Allosteric inhibitors have been used in many early trials in advanced solid tumors, the preliminary efficacy of the MK-2206 and trastuzumab combination in phase I trials for HER2-positive advanced breast and gastroesophageal tumors has been demonstrated through a study on various subtypes of breast cancer.[145]. Here, ERBB2 is linked to breast cancer.